Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Last trade$159.20
Day change-$1.00 (-0.62%)
Day range$158.36 – $160.99
Volume972,563
Market cap$302.56B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$302.56B
Price / earnings
44.78×
Price / book
4.18×
Price / sales
6.08×
EV / sales
6.29×
EV / EBITDA
24.77×
Profitability
Earnings per share
$3.58
Return on assets
5.14%
Return on equity
9.33%
Dividend yield
2.14%
Liquidity and leverage
Debt / equity
0.22×
Current ratio
0.9×
Quick ratio
0.65×
Cash ratio
0.22×
Cash flow
Price / cash flow
25.35×
Price / free cash flow
31.23×
Free cash flow
$9.69B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NVS, quarterly periods
Line item
Q2 FY2016 Jun 30, 2016
Q1 FY2016 Mar 31, 2016
Q4 FY2015 Dec 31, 2015
Q3 FY2015 Sep 30, 2015
Q2 FY2015 Jun 30, 2015
Q1 FY2015 Mar 31, 2015
Q4 FY2014 Dec 31, 2014
Q3 FY2014 Sep 30, 2014
Revenue
$12.68B
$11.81B
$12.8B
$12.49B
$12.9B
$12.2B
$13.35B
$13.3B
Cost of revenue
$4.45B
$4.21B
$4.55B
$4.39B
$4.49B
$3.98B
$4.42B
$4.42B
Gross profit
$8.23B
$7.6B
$8.26B
$8.1B
$8.41B
$8.22B
$8.94B
$8.88B
Selling, general and administrative
$3.65B
$3.31B
$3.89B
$3.46B
$3.62B
$3.28B
$3.97B
$3.57B
Research and development
$2.19B
$2.04B
$2.47B
$2.19B
$2.21B
$2.07B
$2.54B
$2.16B
Total operating expenses
$6.37B
$5.35B
$6.36B
$5.65B
$6.49B
$5.35B
$6.5B
$5.73B
Operating income
$1.85B
$2.25B
$1.9B
$2.44B
$1.92B
$2.87B
$2.44B
$3.15B
Interest expense
-$180M
-$185M
-$158M
-$154M
-$164M
-$179M
-$188M
-$182M
Income before taxes
$2.11B
$2.35B
$1.13B
$2.17B
$2.16B
$2.68B
$2.76B
$3.53B
Income taxes
$307M
$341M
$77M
$357M
$300M
$372M
$308M
$430M
Net income
$1.81B
$2.01B
$1.06B
$1.9B
$1.84B
$13.01B
$1.49B
$3.24B
Net income attributable to common shareholders
$1.8B
$2.01B
$1.05B
$1.89B
$1.84B
$13.01B
$1.49B
$3.22B
EBITDA
$3.32B
$3.62B
$1.9B
$3.8B
$3.43B
$4.16B
$2.44B
$4.32B
Basic earnings per share
$0.76
$0.85
$0.46
$0.79
$0.76
$5.40
$0.63
$1.33
Diluted earnings per share
$0.75
$0.84
$0.45
$0.77
$0.75
$5.32
$0.61
$1.31
Recent news
Company coverage with links to the original publishers.
Incyte announced European Commission approval for Povofortay (povorcitinib) 45 mg and 75 mg for treating moderate to severe hidradenitis suppurativa in adults. The approval is based on STOP-HS1 and STOP-HS2 studies showing durable efficacy through Week 54, with up to 71.4% of patients achieving HiSCR50. Povofortay is the first once-daily oral treatment approved in the EU for this indication. FDA review for U.S. approval is ongoing, with anticipated approval in Q1 2027.
Roche received FDA approval for Wilserdly (giredestrant) combined with everolimus to treat ER-positive, HER2-negative, ESR1-mutated breast cancer. The evERA study demonstrated a 62% reduction in progression or death risk compared to standard therapy. The drug is also under FDA review for adjuvant treatment, with a decision expected by November 2026, potentially expanding its market opportunity.
The FDA approved Novartis's Cosentyx (secukinumab) 150 mg for treating polymyalgia rheumatica in adults with inadequate response to or intolerance of corticosteroids. In the Phase III REPLENISH trial, Cosentyx doubled sustained remission rates (40.5% vs 20.5%) compared to placebo and demonstrated steroid-sparing effects. This marks the 11th US indication for Cosentyx and the first anti-IL-17 biologic approved for PMR, offering an alternative to long-term steroid use which carries significant health risks.
Novo Nordisk received European Commission approval for Frehemgo (denecimig), a next-generation bispecific antibody for hemophilia A prophylaxis. The company also presented positive Phase III data for CagriSema, showing 20.7-21.0% weight loss at 68 weeks versus 2.0% for placebo, with FDA decision expected in Q4 2026. However, Novo faces intensifying competition from Eli Lilly's obesity and diabetes drugs.
Novartis (NVS) is highlighted as a strong momentum pick with a Zacks Rank #2 (Buy) rating and Momentum Style Score of B. The pharmaceutical company has shown positive price performance, outperforming its industry peers over multiple timeframes, with shares up 1.09% weekly and 21.19% annually. Recent earnings estimate revisions have been consistently upward, with 6 higher estimates for the full year and 7 upward revisions for the next fiscal year, supporting its bullish outlook.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Mar 11, 2026
$4.7402
Mar 16, 2026
recurring
Mar 12, 2025
$3.994
Apr 25, 2025
recurring
Mar 7, 2024
$3.7395
Apr 19, 2024
recurring
Mar 9, 2023
$3.4987
Mar 20, 2023
recurring
Mar 8, 2022
$3.3252
Mar 17, 2022
recurring
Stock splits
Historical share-structure events and their execution dates.